论文部分内容阅读
本文对近年来新开发的非交叉耐药的抗白新药作一介绍.MX:2(3(?)-deamino-3(?)morpholino-13-deoxo-10-hydroxy(?)ar(?)inomycin)是半合成新型吗啉蒽醌药,对L(?)白血病,Lewis 肺癌、结肠癌,Colon 26等小鼠实验性肿瘤及移植性(?)鼠MX-1人乳腺癌比ADM 效果好.对耐ADM 的小鼠和人白血病细胞的效果和敏感株几乎相同.Ⅰ期临床研究结果其白细胞减少是剂量限制因素,另外还有轻度恶心、呕吐、脱发、口腔炎及血小板减少,无急性、亚急性心脏毒性.Ⅱ期临床研究正在进行,主要用于耐ADM 的白血病.
In this paper, a new development of non-cross-resistance anti-white drugs is introduced in recent years. MX: 2(3(?)-deamino-3(?)morpholino-13-deoxo-10-hydroxy(?)ar(?) Inomycin) is a novel semi-synthetic morphine drug, effective against L(?) leukemia, Lewis lung cancer, colon cancer, colon 26 and other mouse experimental tumors, and transplantable (?) mouse MX-1 human breast cancer than ADM. The effects and sensitive strains of mice and human leukemic cells resistant to ADM are almost identical. Phase I clinical studies showed that leukopenia is a dose limiting factor, as well as mild nausea, vomiting, hair loss, stomatitis, and thrombocytopenia. Acute, subacute cardiotoxicity. Phase II clinical studies are ongoing and are mainly used for leukemic patients resistant to ADM.